Arecor boasts "favourable profile” for fast-acting insulin in phase I trial

Arecor expects to begin a "very quick" phase II trial next year as it takes its first drug through clinical trials

Arecor -

Arecor Ltd has hailed the successful completion of a phase I trial for its ultra-rapid acting insulin for diabetics, which it said had a “favourable profile” when compared with standard treatments.

In an upbeat statement on Thursday, the private biotech company said that its candidate, AT247, had finished a phase I double-blind, randomised study at The Medical University of Graz and Joanneum Research in Austria, in which it was measured against two other insulins on the market, NovoRapid and Fiasp.

READ: Arecor punches above its weight with trials for fast-acting diabetes drugs

Complete results from this study have been submitted for publication at “a major diabetes conference” in 2020.  

Sarah Howell, chief executive officer of Arecor, called the study's completion “an important step” for the company’s goal to improve treatment and healthcare outcomes for people living with Type I diabetes.

“With AT247’s favourable profile over current treatments, we believe that our products have the potential to advance the diabetic treatment landscape," Howell said, noting that full data from the phase I study will be reported "in due course".

AT247 is the first drug that the ex-Unilever spinout Arecor has taken through clinical trials, as it moves away from big pharma contracts to developing its own portfolio.

Working to improve an existing treatment - insulin - gives Arecor the chance to fast-track the development process, since it has already been proven to work.

Howells said in November that Arecor expects a “very quick phase II study” to begin within the next calendar year, before it moves AT247 into phase III.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...


Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product. As Howell explains, this deal follows on from the first...

6 days, 19 hours ago

2 min read